



# City Therapeutics Enters Strategic Collaboration with Bausch + Lomb

Client News

January 10, 2025

Gunderson Dettmer represented client [City Therapeutics](#), a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, in its strategic collaboration with Bausch + Lomb, a global eye health leader focused on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) that causes irreversible vision loss. Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Under terms of the collaboration, City Therapeutics has received an upfront cash payment and, if Bausch + Lomb elects to pursue a candidate for further development, City Therapeutics is also eligible to receive contingent payments tied to development, regulatory, commercial and sales milestones of up to \$485 million, as well as tiered royalty payments on net product sales.

In the [announcement of the strategic collaboration](#), City Therapeutics CEO Andy Orth said, “We are excited to collaborate with Bausch + Lomb’s team of eye health experts, who share our vision to expand the reach of RNAi-based medicines for people living with serious unmet medical needs such as GA. We look forward to delivering a new treatment option for the more than one million people in the U.S. living with GA. For City Therapeutics, this marks our first major corporate collaboration, and it enables significant funding to advance our platform of innovative RNAi trigger molecules for broader applications in ophthalmologic diseases.”

The Gunderson Dettmer team was led by Brendan McCarthy and included Brittany Nicely.

## Companies

City Therapeutics

Bausch + Lomb

## Related People



Brendan C. McCarthy

PARTNER

P +1 858 436 8013



Brittany M. Nicely

ASSOCIATE

P +1 858 436 8067

## Related Services

Early-Stage Company

Life Sciences

Life Sciences Licensing & Strategic Partnering

## Featured Insights

### CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

### CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

### CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

### CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

### CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

### INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

### CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

### INSIGHTS

Client Insight: California AI Transparency Act

### INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

### INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)